Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will…
tryptamine
Cybin’s (CYBN.NE) subsidiary Adelia Therapeutics completed earnout milestones originally set in a contribution agreement for the period of January 1, 2021, following Cybin’s acquisition of Adelia. There are a…
Algernon Pharmaceuticals (AGN.C) awarded the contract for the synthesis and manufacture of the psychoactive ingredient and finished product for its AP-188 DMT project to Canadian-based Dalton Pharma Services today,…